| Document |
Document Title |
|
WO/2013/079024A1 |
The present invention belongs to the fields of natural medicine and medicinal chemistry, and relates particularly to new oleanolic acid amidate derivatives of general formula I or pharmaceutically acceptable salts thereof, preparation me...
|
|
WO/2013/071722A1 |
A method for producing 30-halogenated betulinic acid. Betulin is used as a raw material, and is selectively oxidized and halogenated to generate 30-betulinic acid, and the selected oxidation and halogenation agent has high selectivity an...
|
|
WO/2013/043778A1 |
Compounds of Formula I: that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.
|
|
WO/2013/038316A1 |
The present invention relates to a method for preparation of betulinic acid from betulin. The method comprises oxidizing betulin to betulinic acid with a catalyst of formula (5), e.g. 2,2,6,6-tetramethylpiperidine 1 - oxyl (TEMPO), in th...
|
|
WO/2013/038314A1 |
The invention relates a method for preparation of betulonic acid or betulinic acid from betulin wherein the method comprises a stage for oxidizing betulin to betulonic aldehyde and/or betulinic aldehyde with Pd(ll)-catalyst catalyzed oxi...
|
|
WO/2013/038312A1 |
The present invention relates to a method for preparation of betulinic acid from betulin. The method comprises oxidizing betulin to betulinic and/or betulonic aldehyde with a ruthenium based catalyst catalyzed oxidation process in the pr...
|
|
WO/2013/020246A1 |
A compound characterized by the following formula (I) or a pharmaceutically acceptable salt thereof, wherein R, L and A are as described herein is provided by the present invention. Compounds of the present invention are useful for the t...
|
|
WO/2013/001890A1 |
[Problem] To provide a soy saponin composition having high bodily absorption characteristics. [Solution] This soyasapogenol composition contains soyasapogenol B and 3-O-D-glucuronopyranosyl soyasapogenol B. The weight ratio (B/A) of the ...
|
|
WO/2012/171377A1 |
Disclosed is a crystal form A of asiatic acid trometamol salt, showing main peaks at diffraction angle (2θ) of 5.98, 6.87, 9.12, 10.38, 12.00, 12.47, 12.93, 13.42, 14.72, 15.10, 17.01 and 18.14 degree, and minor peaks at diffraction ang...
|
|
WO/2012/160250A2 |
The present invention provides an improved method for obtaining a bark extract by hydrolysis and acidification in the presence of water. The method comprises the steps of subjecting birch bark to hydrolysis; separating the undissolved ba...
|
|
WO/2012/126363A1 |
Disclosed are an amorphous asiatic tromethamine salt and the preparation method thereof. The method comprises the steps of: (1) dissolving asiatic acid in an organic solvent; (2) mixing with tromethamine; (3) stirring and salifying the s...
|
|
WO/2012/125488A1 |
Disclosed herein are novel C4-monomethyl triterpenoid compounds and derivatives thereof, including those of the formula (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of man...
|
|
WO/2012/119458A1 |
Disclosed are the general structural formula of LQC-Y as well as the synthesis and use thereof. Pharmacological experiments demonstrated the marked antitumor effect of such compounds. Single day administration of LQC-Y3 to mice at a maxi...
|
|
WO/2012/106188A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-28 amines of C-3 modified betulinic acid derivatives that possess unique antiviral activity are prov...
|
|
WO/2012/106190A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturat...
|
|
WO/2012/100389A1 |
Disclosed are a series of pentacyclic triterpenoid compounds, preparation methods and uses thereof. The compounds have anti-inflammatory, anti-tumor, anti-bacterial and antiviral activities, and they can be used for treating urinary inco...
|
|
WO/2012/095705A1 |
The present invention relates to certain novel salts of Betulinic acid derivatives, to process for preparing such compounds, to use the compounds in treating diseases or disorders mediated by HIV infection, to methods for their therapeut...
|
|
WO/2012/083112A2 |
Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula (Z), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), or (XVII). Also described herein are pharmaceutical compositions that include at least one compound...
|
|
WO/2012/020021A9 |
The present invention encompasses compounds of general formula (I) wherein R3a to R31 and X are defined as in claim 1, which are suitable for the treatment of and/or prevention of chronic inflammatory diseases, autoimmune diseases, skin ...
|
|
WO/2012/024893A1 |
Chemical entities which are triterpenoid derivatives, pharmaceutical compositions and methods of treatment of inflammatory, neurodegenerative, neoplastic and autoimmune diseases are described.
|
|
WO/2012/022780A1 |
The invention relates to the medical and cosmetic field, more precisely the field of anticancer treatment and treatment of inflammatory diseases and diabetes and the field of anti-aging or anti-wrinkling agents using newly synthesized 18...
|
|
WO/2012/006864A1 |
Disclosed are a series of pentacyclic triterpenoid compounds, preparation methods and uses thereof. The compounds have anti-inflammatory, anti-tumor, anti-bacterial and antiviral activities, and they can be used for treating urinary inco...
|
|
WO/2011/153315A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess u...
|
|
WO/2011/153319A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided a...
|
|
WO/2011/138460A1 |
The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.
|
|
WO/2011/074608A1 |
Disclosed is a prophylactic or therapeutic agent for chronic hepatitis C, which contains a triterpene derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. (In formula (I), R...
|
|
WO/2011/074607A1 |
Disclosed is a triterpene derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed is a prophylactic or therapeutic agent for chronic hepatitis C, which contains the above-described trit...
|
|
WO/2011/007230A2 |
The invention relates to novel lupeol-type triterpene derivatives and related compounds, and pharmaceutical compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.
|
|
WO/2010/139253A1 |
A compound represented by formula II, a preparation method and uses thereof in treating liver damage, inflammation and so on are disclosed. A method for preparing glycyrrhetinic acid derivatives are also disclosed. In the compound repres...
|
|
WO/2010/103046A1 |
The present invention encompasses novel triterpene compounds of general formula I, wherein R3a, R3b, R11a, R11 b, R31 and R32 are defined as in claim 1, which are suitable for the prevention and/or treatment of diseases mediated by 11 β...
|
|
WO/2010/054606A2 |
The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X1 and R2 contains a 2-deoxy glycosidic group, method of preparation thereof, their cytotoxic activity and a pha...
|
|
WO/2010/044371A1 |
A sweet taste receptor agonist such as acesulfame K, sucralose, saccharin or glycyrrhizin can be used as an active ingredient for an insulin secretion stimulator. A candidate substance for an insulin secretion stimulator can be screened...
|
|
WO/2010/032123A1 |
The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by in...
|
|
WO/2010/029915A1 |
Disclosed is a simple method for producing a plant containing sapogenin, which contains a large quantity of sapogenin and has outstanding taste and safety, using a plant containing saponin as the raw material. The method for producing a ...
|
|
WO/2010/007788A1 |
Disclosed is a gap junction inhibitor which is more practically useful compared with carbenoxolone. Also disclosed is a novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by general formula (1) or (2).
|
|
WO/2009/151035A1 |
Disclosed is a therapeutic agent for overactive bladder, which comprises a glycyrrhetinic acid component or a pharmaceutically acceptable salt thereof. The therapeutic agent is particularly effective on myogenic overactive bladder or ov...
|
|
WO/2009/146619A1 |
A method for producing betulinic acid uses betulin as the starting material and comprises the following steps: (1) betulin is oxidized to prepare betulin aldehyde crude product; (2) betulin aldehyde crude product is oxidized to obtain be...
|
|
WO/2009/146216A2 |
Disclosed herein are novel oleanolic acid derivatives. Methods of preparing these compounds are also disclosed. The oleanolic acid derivatives of this invention may be used for the treatment and prevention of many diseases, including can...
|
|
WO/2009/135352A1 |
A plum tree extract comprises 0.5-50 wt% squalene The plum tree extract mainly comes from fat-soluble portion and/or water-soluble portion of non-fruit part of plum tree A method for preparing the plum tree extract, comprises using super...
|
|
WO/2009/129546A1 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising suc...
|
|
WO/2009/129545A1 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising suc...
|
|
WO/2009/129548A1 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising ...
|
|
WO/2009/117987A2 |
The present invention relates to new boswellia acid derivatives. The present invention furthermore relates to the use of preparations with boswellia acid derivatives or synthetic derivatives, especially with boswellia acid derivatives, w...
|
|
WO/2009/100532A1 |
The invention relates to 17ß lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the inventi...
|
|
WO/2009/094958A1 |
This invention relates to saccharide lupane derivatives of general formula (I), wherein R denotes substituent independently selected from the group comprising hydrogen, hydroxy, amino, mercapto, alkyloxy, alkyl and saccharide group, R´ ...
|
|
WO/2009/082818A1 |
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/082819A1 |
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/072916A1 |
Friedelin is a natural compound with promising proprieties. On its own or with chemical modification it is possible to introduce relevant biological activities, e. g., anti-cancer, anti-aging and agrochemical. Its availability in signifi...
|
|
WO/2009/067891A1 |
The invention discloses water-soluble triterpenephenol compounds having antitumor activity represented by formula (I), wherein the substituents R1-R4 and M are defined as in the description. The invention also discloses a method for prep...
|
|
WO/2009/060601A1 |
Disclosed is a novel derivative having remarkable curative effects on malignant tumors, for which a natural triterpene compound serves as a lead compound. Specifically disclosed is an agent for treatment of malignant tumors, which contai...
|
